Sangamo Therapeutics, Inc.

Good afternoon and welcome to the Sangamo Therapeutics Second Quarter 2025 teleconference call. Please be advised that today's conference is being recorded. I would now like to turn the conference over to your speaker today, Louise Wilkie, Head of Investor Relations and Corporate Communications. Please go ahead.

Thank you. Good afternoon, everyone. Thank you for joining us on the call today. this call are several members of the sangamo executive leadership team including sandy mccray chief executive officer natalie dubois string fellow chief development officer and prasusha durababu chief financial officer slides from our corporate presentation can be found on our website sangamo.com and under the presentations page of the investors and media section this call includes forward-looking statements regarding sangamo's current expectations these statements include but are not limited to statements relating to Sangamo's cash runway, Sangamo's plans to obtain additional capital and its ability to continue to operate as a going concern, the therapeutic and commercial potential and value of Sangamo's product candidates and technologies, Sangamo's ability to establish and maintain collaborations and strategic partnerships, including for its Fabry disease program, the anticipated plans and timelines of Sangamo and its collaborators for clinical trials, clinical data presentations and releases, regulatory submissions and regulatory approvals, upcoming catalysts and milestones, and other statements that are not historical fact. Actual results may differ materially from what we discussed today. These statements are subject to certain risks and uncertainties that are discussed in our filings of the SEC, specifically in our annual report on Form 10-K for the fiscal year ended December 31, 2024, and our quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2025, and subsequent filings and reports that Sangoma makes from time to time with the SEC. The forward-looking statements stated today are made as of today and we undertake no duty to update such information except as required by law. Please note that all forward-looking statements about our future plans and expectations are subject to our ability to secure adequate additional funding. Now, I'll turn the call over to our CEO, Sandy McRae.

Thank you, Louise, and good afternoon to everyone joining the call today. This quarter, we made important advances across both our clinical and preclinical pipelines. In June, we were happy to announce the positive top line results from a registrational star in Fabry Disease, taking us one step closer on the path towards potential approval of this promising treatment for Fabry Disease patients. This month, we also became a clinical stage neurology genomic medicine company with the initiation of our first clinical site in the Phase 1-2 STAND study in chronic neuropathic pain. This is an important achievement. It means we are on track to generate clinical data for this programme anticipated towards the end of 2026. Finally, earlier this quarter, we held a productive meeting with the UK's Medicines and Healthcare Product Regulatory Agency, or MHRA, for our pre-clinical prion disease programme and are on track for a planned CTA submission for this programme as early as mid-2026. I'm proud of the progress and proud of my Sangamo colleagues who continue to work tirelessly to advance our pipeline while operating in such a challenging environment. Let me now hand directly to Natalie Dubois-Stringfellow, our Chief Development Officer, to provide more context on these important programs. I will then close the call by summarizing the key takeaways from this quarter, and we'll put these updates into perspective. Natalie.